In the last trading session, 5.6 million shares of the Gilead Sciences, Inc (NASDAQ:GILD) were traded, and its beta was 0.31. Most recently the company’s share price was $108.00, and it changed around -$2.83 or -2.55% from the last close, which brings the market valuation of the company to $134.34B. GILD currently trades at a discount to its 52-week high of $119.96, offering almost -11.07% off that amount. The share price’s 52-week low was $62.69, which indicates that the current value has risen by an impressive 41.95% since then. We note from Gilead Sciences, Inc’s average daily trading volume that its 10-day average is 7.29 million shares, with the 3-month average coming to 9.25 million.
Gilead Sciences, Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.87. If we narrow it down even further, the data shows that 0 out of 30 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 11 recommended GILD as a Hold, whereas 15 deemed it a Buy, and 0 rated it as Underweight. Gilead Sciences, Inc is expected to report earnings per share of 1.95 for the current quarter.
Gilead Sciences, Inc (NASDAQ:GILD) trade information
Instantly GILD has showed a red trend with a performance of -2.55% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 112.09 on recent trading dayincreased the stock’s daily price by 3.65%. The company’s shares are currently up 16.92% year-to-date, but still down -1.90% over the last five days. On the other hand, Gilead Sciences, Inc (NASDAQ:GILD) is 5.37% up in the 30-day period. We can see from the shorts that 20.94 million shares have been sold at a short interest cover period of 2.39 day(s).
The consensus price target as assigned by Wall Street analysts is $126, which translates to bulls needing to increase their stock price by 14.29% from its current value. Analyst projections state that GILD is forecast to be at a low of $83 and a high of $132.
Gilead Sciences, Inc (GILD) estimates and forecasts
The year-over-year growth rate is expected to be -0.33%, down from the previous year.
Consensus estimates provided by 19 financial analysts predict the company will bring in an average of 6.96B in revenue for the current quarter. 18 analysts expect Gilead Sciences, Inc to make 7.39B in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 6.95B and 7.54B respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 0.04%. Forecasts for the next quarter put sales growth at -2.01%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -38.13%. Gilead Sciences, Inc earnings are expected to increase by 72.27% in 2025, but the outlook is positive 25.83% per year for the next five years.
GILD Dividends
Gilead Sciences, Inc’s next quarterly earnings report is expected to be released on 2025-Apr-23. The annual dividend yield of the stock is 2.89 percent and its annual dividend per share was 3.12. It is important to note, however, that the 2.89% dividend yield ratio should be regarded as a guide only, as many other factors should be taken into consideration before making any investment decision. The average dividend yield for the past five years averaged 3.96 per year.
VANGUARD GROUP INC, with 9.2431% or 115.26 million shares worth $7.91 billion as of 2024-06-30, holds the second largest percentage of outstanding shares.
